Media Center

Mon, 01 Apr 2024

Clinical Collaboration Agreement Established between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement

Thu, 29 Feb 2024

Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes Joint Steering Committee between Launch Therapeutics and Gilead Sciences

Wed, 31 May 2023

Pathalys Pharma and Launch Therapeutics Announce First Patient Enrolled Ahead of Schedule in Pivotal Phase 3 Program for Upacicalcet in Patients Receiving Hemodialysis

Wed, 12 Apr 2023

Launch Therapeutics Selects Medidata AI Intelligent Trials to Accelerate Clinical Trial Development

Wed, 18 Jan 2023

Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies

Mon, 15 Aug 2022

Launch Therapeutics partners with Opthea to advance OPT-302, a promising therapy for wet AMD

Mon, 11 APRIL 2022

Carlyle Expands Leading Healthcare Franchise with Agreement to Acquire Life Sciences Investment Firm Abingworth